Panobinostat is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
November 30, 2021 - Secura Bio has submitted to FDA for the withdrawal of the approval of NDA 205353 for FARYDAK® (panobinostat) oral capsules.
The accelerated approval was based on progression-free survival and consistent with FDA regulations, required further adequate and well-controlled clinical studies to verify and describe the product's clinical benefit. In its withdrawal submission, Secura Bio noted that, as previously discussed with FDA, it was not feasible for the company to complete the required post-approval clinical studies as designed as part of the accelerated approval process. Because those studies were required to verify and describe the clinical benefit of the drug product, the clinical benefit of FARYDAK has not been confirmed under the specific constraints of the accelerated approval process.Learn more